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Objective: To investigate the anti-inflammatory effect
of erythropoietin (EPO) pretreatment on cardiomyocytes ex-
posed to hypoxia/reoxygenation injury (H/R) and explore
the possible mechanism.
Methods: The cultured neonatal rats’ ventricular
cardiomyocytes were divided randomly into 4 groups, con-
trol group (C group), EPO pretreatment group (E group),
EPO and pyrrolidine dithiocarbamate (PDTC) pretreatment
group (EP group) and PDTC pretreatment group (P group).
After 24 hours’ pretreatment, the cardiomyocytes were ex-
posed to H/R. After pretreatment and H/R, the expression of
tumor necrosis factor-(TNF-) gene in all the groups
was detected by RT-PCR and Western blot. The nuclear
factor-B (NF-B) activity was detected by electrophoretic
mobility shift assay (EMSA) and the inhibitor-B (I-B)
protein level was detected by Western blot.
Results: The decrement of I-Bprotein and the in-
creasing NF-B activity were found in cardiomyocytes pre-
treated with EPO beforeH/Rcompared to other groups (t=3.321,
4.183, P<0.01). However, after H/R, NF-Bactivity and ex-
pression of TNF-gene were significantly reduced, I-B
protein expression was increased in cardiomyocytes of E group
compared to other groups (t=3.425, 3.687, 3.454, P<0.01). All
theses changes caused by EPO pretreatment were eliminated
by the intervention of PDTC (an antagonist to NF-B) dur-
ing pretreatment.
Conclusions: EPO pretreatment can inhibit the activa-
tion of NF-B and upregulation of TNF- gene in
cardiomyocytes exposed to H/R through a negative feed-
back of NF-B signaling pathway, and thus produces the
anti-inflammatoryeffect. This might be one of the ways EPO
produces the anti-inflammatory effect.
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Erythropoietin (EPO) is a haematopoieticcytokine, which has been used to treat anemia.Recently, it has been found that EPO can pro-
tect organs, tissues and cells, including nervous tissue,
kidney, intestine, vascular endothelial cell, vascular
smooth muscle cell and skin, against different detri-
mental factors. This non-haematopoietic effect of EPO
has been noticed by many researchers. EPO’s car-
diac protective effect has been reported in recent years,
which is an encouraging finding for the study of cardiac
protection in the clinical environment. Anti-apoptosis
and anti-inflammation are thought to be the two main
mechanisms of this protective effect, but the associ-
atedsignaling pathwaysneedclarification. In thepresent
study, the possible pathway in which EPO produces
anti-inflammatory effect in cardiomyocytes exposed to
H/R was explored.
METHODS
Reagents
DMEM/F12 culture medium and fetal bovine serum
(Hyclone, USA), recombinant human erythropoietin
(rhEPO, Zhongshan, China), pyrrolidine dithiocarbam-
ate (PDTC, Sigma, USA), I-B, TNF-monoclonal
antibody (Sigma, USA), RT-PCR kit (Dingguo, China),
Western blot kit (Zhongshan, China), electrophoretic
mobility gel shift assay (EMSA) kit (Novagen, USA).
Culture of cardiomyocytes
All animals received humane care in compliance
with the European Convention onAnimal Care and this
study was approved by our institutional ethics
committee. 1-day-old Sprague-Dawley rats were pro-
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vided by the animal center of the ThirdAffiliated Hospi-
tal of Third Military Medical University in China. Hearts
were taken out under aseptic condition, placed into a
Petri dish with some cold D-Hanks and then washed
twice. The ventricular myocardium was moved to an-
other Petri dish and cut into small pieces (about 1 mm3).
0.125% trypsin was added and after 7 minutes’
dispersion, the supernatant was abandoned. Trypsin
was added again and after 7 minutes’ dispersion the
supernatant was moved to a centrifuge tube. The
DMEM/F12 culture medium with 20% fetal bovine se-
rum was used to terminate the dispersion. The disper-
sion was repeated about 10 times. The collected
cardiomyocyte suspension was filtered, and then cen-
trifuged at 1500×g for 5 minutes. The sediment was
suspended wi th cul t ure m ed ium and the
cardiomyocytes were purified by the differential attach-
ment procedure, which then were cultured in the 25 ml
culture bottles. The bottles were placed into the incu-
bator containing 5% CO2and the temperaturewas main-
tained at 37°C. Cardiomyocytes cultured for 72 hours
were used.
Treatment protocols
The cardiomyocytes were divided into four groups,
including control group (C group), EPO pretreatment
group (rhEPO 10 units/ml medium, E group), EPO+
PDTC pretreatment group (rhEPO 10 units and PDTC
5 µg/ml medium, EP group), and PDTC pretreatment
group ( PDTC 5µg/ml medium, P group).After 24 hours’
pretreatment, cardiomyocytes were exposed to H/R.
After pretreatment and H/R, 8 samples were collected
from each group for the molecular biological assay.
H/R injury of cardiomyocytes
 The hypoxia solution (NaH2PO4 0.9 mmol/L ,
NaHCO3 6.0 mmol/L, CaCl2 1.0 mmol/L, MgSO4 1.2
mmol/L, sodium lactate 40 mmol/L, 4-(2-hydroxyethyl)
piperazine-1-ethanesulfonic acid (HEPES) 20 mmol/L,
NaCl 98.5 mmol/L, KCl 10.0 mmol/L, pH 6.8, 37°C)
was saturated with >99.9% N2 (1l.minutes
–1 x30
minutes), and the reoxygenation solution (NaH2PO4 0.
9 mmol/L, NaHCO3 20 mmol/L, CaCl2 1.0 mmol/L,
MgSO4 1.2mmol/L, glucose5.5mmol/L,HEPES20mmol/
L, NaCl 129.5 mmol/L, KCl 5.0 mmol/L, pH7.4, 37°C)
was saturated with pure O2. Replacing normal culture
medium with hypoxia solution caused hypoxia and re-
placing hypoxia solution with reoxygenation solution
simulated reoxygenation. The hypoxia lasted 30 min-
utes and the reoxygenation lasted 2 hours.
RT-PCR for the expression of TNF-mRNA
Cardiomyocytes were lysed with TRIZOL solution
to extract the total RNA, which was reversely tran-
scribed to cDNA. The latter was amplified by PCR. The
primer of rat TNF- cDNA was designed and provided
by Shengong (Shanghai, China). The sequence of the
positive-sensestrandwas 5’-CTTCTCATTCCTGCTCGT
GG-3’and the sequence of the negative-sense strand
was 5’-TCCTCCGCTTGGTGGTTT-3’.Theamplifiedse-
quence was 204 bp.-actin was the internal reference
gene, whose amplified sequence was 540 bp. The de-
tailed parameters of the PCR were as fol lows:
apomorphosis at 94°C for 2 minutes first, then amplifi-
cation for 30 circles (apomorphosis at 94°C for 45
seconds, anneal at 58°C for 30 seconds and extension
at 72°C for 30 seconds) and extension at 72°C for 5
minutes at last. The PCR product was separated by
2% agarose gel electrophoresis, and the gel was ana-
lyzed with a Bio-Rad Calibrated Densitometer.
Western blot for the expression of TNF-and I-B
protein
Cardiomyocytes were lysed with lysis buffer con-
taining 10 mmol/L Tris–HCl, 5 mmol/L MgCl2, 10 mmol/
L KCl, 0.3 mmol/L ethyleneglycol bis (2-aminaethyl
ether) tetraacetic acid (EGTA), 0.5 mmol/L DTT, 0.3
mol/Lsucrose,1mmol/Lphenylmethanesulfonyl fluoride
(PMSF, a protease inhibitor), and 0.5% NP-40, and the
mixture was centrifuged. The supernatant was saved
for cytosolic protein analysis. Concentration of each
sample was measured with coomassie brilliant blue.
The protein concentrations of samples were equal in all
experiments. Proteins were separated by sodium
dodecyl sulfate polyacrylamide gel electropheresis
(SDS-PAGE), transferred to polyvinylidene difluoride
(PVDF) membrane, and incubatedwith monoclonal anti-
bodies to TNF- or I-B. The membranes were incu-
bated with secondary antibody (Zhongshan, China) for 2
hoursanddevelopedwithenhancedchemiluminescence
(ECL) reagent (Zhongshan, China). ECLwas detected
with an LAS-1000 (Fuji film, Japan). Film was scanned
and the intensity of immunoblot bands was detected
with a Bio-Rad Calibrated Densitometer.
NF-B electrophoretic mobility gel-shift assay
Nuclear protein was extracted by modifying a previ-
ously described technique.1 Cells were collected with
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analyzed by analysis of variance (ANOVA). P < 0.05
was considered significant and P < 0.01 was consid-
ered very significant.
RESULTS
Expression of TNF-gene in different groups be-
fore and after H/R
There was no significant difference in the expres-
sion of TNF-gene between the 4 groups before H/R
based on the findings from Western blot and RT-PCR
(Table 1, Figs.1 and 2).
The results of Western blot and RT-PCR showed
that the expression of TNF-gene was significantly
upregulated in all the groups after H/R. TNF-gene was
expressed less in E group than in the other 3 groups
(t=3.681, P<0.01, Table 1, Figs. 1 and 2).
Expression of I-B protein in different groups
before and after H/R
Before H/R, I-Bprotein was expressed less in
the E group than in the other 3 groups (t=3.321, P<0.01).
I-Bprotein in EP group and P group was expressed
a little more than that in C group, but the difference was
not significant (P>0.05). After H/R, I-Bprotein de-
creased significantly in all the groups except for E group
compared to that before H/R, which was higher in E
group than in the other groups (t=3.454, P<0.01, Table 1,
Fig.3).
Changes of NF-B activity in different groups be-
fore and after H/R
The results of EMSA showed that NF-B activ-
ity in E group was higher than that in the other groups
after 24hours’pretreatment beforeH/R (t=4.183, P<0.01,
Table 1, Fig.4A).
Table 1. Changes of the molecular biological markers in different groups (n=8,  ± s)
Before H/R After H/R
C group E group EP group P group
TNF-mRNA/
 -actin mRNA
TNF- protein
(Odu*mm2)
I-Bprotein
(Odu*mm2)
NF- B activity
(Odu*mm2)
C group E group EP group P group
0.093±0.012
0.11±0.02
0.47±0.11
0.38±0.07
0.091±0.011
0.10±0.01
0.30±0.05**
1.08±0.14**
0.093±0.015
0.13±0.01
0.52±0.14
0.34±0.08
0.092±0.011
0.12±0.03
0.50±0.09
0.31±0.03
0.58±0.11
0.54±0.06
0.17±0.02
2.23±0.23
0.39±0.10**
0.31±0.07**
0.28±0.07**
1.38±0.17 **
0.54±0.05
0.50±0.15
0.18±0.03
2.16±0.31
0.57±0.05
0.51±0.05
0.17±0.03
2.19±0.22
**P<0.01: vs C group ;  P<0.05,  P<0.01: vs before H/R.
a cell scraper and washed twice with ice-cold PBS.
The cell pellet was resuspended in 400 ml of lysis buffer
containing 10 mmol/L Hepes (pH 7.9), 10 mmol/L KCl,
1 mmol/LEGTA, 1 mmol/LDTT, and complete protease
inhibitor tablets (Sigma, USA). Cells were incubated
on ice for 15 minutes in lysis buffer. NP-40 (Sigma,
USA) was added to a final concentration of 0.5%, and
the sample was vortexed for 10 seconds. The sample
was then centrifuged at 8 000×g for 15 minutes at 4°C.
The nuclear pellet was resuspended in 50 ml of nuclear
extractionbuffer [20mmol/L HEPES (pH7.9), 0.4mmol/
L NaCl, 1 mmol/L EGTA, 1 mmol/L DTT, and complete
protease inhibitor tablets] and the tube placed on ice for
30 minutes with gentle vortexing every 10 minutes. The
nuclear extract was then centrifuged at 12 000×g for 5
minutes at 4°C. The supernatant (nuclear fraction) was
collected and stored at -70°C. Protein concentration
was measured in nuclear extracts with the coomassie
brilliant blue.
NF-B consensus oligonucleotide 5’AGTTGAG
GGGACTTTCCCAGGC-3’ (Shengong, China) was
5’end-labeled with [r-32P] ATP using T4 polynucleotide
kinase. Unincorporated nucleotide was removed. 6 µg
of nuclear protein was incubated with 2 µl of labeled
oligonucleotide in binding buffer [10 mmol/L Tris-HCl
(pH 7.5), 50 mmol/L NaCl, 0.5 mmol/L EDTA, 1 mmol/
L MgCl2, 0.5 mg poly(dI-dC)-poly(dI-dC),1%NP-40, and
4% glycerol] for 25 minutes at room temperature.
Subsequently. The free oligonucleotide and oligonucle-
otide-bound proteins were separated by electrophore-
sis on a native 4% polyacrylamide gel. The gel was
then dried and exposed to X-ray film. The film was ana-
lyzed with a Bio-Rad calibrated densitometer.
Statistical analysis
Results were presented as ± s. All data were
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DISCUSSION
EPO is a hematopoietic factor responsible for the
production of red blood cells. EPO is induced by hy-
poxia via the hypoxia inducible factor (HIF) family of
transcription factors. Because of its proerythroid action,
EPO has been used to treat anemia caused by differ-
ent disorders, such as renal failure, chemotherapy,
surgical blood loss and so on.2, 3 The non-hematopoi-
etic biological effects of EPO have been found and
highlighted. In particular, many studies have shown that
EPO has direct tissue protective effect on many differ-
ent organs, tissues andcells, including the kidney, brain,
spinal cord, vascular endothelial cell, intestine and skin.4-9
The direct cardioprotection function of EPO has been
reported in recent years, which has raised great inter-
est of some researchers.
Several studies have shown that cardiomyocytes
can express EPO receptor (EPOR). RT-PCR demon-
strated that EPOR mRNA was expressed in adult rat’s
heart.10 Through immunohistochemical staining and
immunoblotting in neonatal rat ventricular cardiac
myocytes, it was found that cardiomyocytes did ex-
press EPOR protein.11 These findings suggest that EPO
may have direct protective effect on myocardium.
After H/R, NF-B was significantly activated in all the
groups compared to that before H/R. However, NF-B
activity in E group was much lower than that in the other
groups (t=3.425, P<0.01, Table 1, Fig. 4B).
H/R Marker – – – – + + +  +
RhEPO – + + – – + + –
PDTC – – + + – – +  +
Fig.1. Expression of TNF-mRNA in different groups before and
after H/R. After 24 hours’ pretreatment, there was no significant
difference in the expression of TNF- mRNA between the 4
groups. After H/R, TNF-mRNA was expressed significantly higher
in all the 4 groups compared to that before H/R. Expression of TNF-
mRNA was lower in E group than in the other 3 groups (t=3.316,
P<0.01).
H/R – – – – + + +   +
RhEPO – + + – – + + –
PDTC – – + + – – +    +
Fig.2. Expression of TNF- protein in different groups before
and af ter H/R detected by Western blot. After 24 hours ’
pretreatment, there was no significant difference in the expres-
sion of TNF- protein between the 4 groups before H/R . After H/R,
the expression of TNF- protein was significantly upregulated in
the 4 groups compared to that before H/R. TNF- protein was
less in E group than in the other 3 groups (t=3.687, P<0.01).
H/R – – – – + + +   +
RhEPO – + + – – + + –
PDTC – – + + – – +    +
Fig.3 Expression of I-Bprotein in different groups before and
after H/R detected with Western blot. Before H/R, I-Bprotein
was less in the E group than in the other 3 groups (t=3.321, P<0.01).
After H/R, I-Bprotein was declined significantly in all the groups
compared to that before H/R. However, I-Bprotein was ex-
pressed more in E group than in the other 3 groups (t=3.454, P<0.01).
RhEPO – + + –
PDTC – – +      +
H/R – + + +    +
RhEPO – – + + –
PDTC – – – +   +
Fig.4 Change of NF- B activity in all the groups before and after
H/R detected with EMSA. A: NF- B activity in E group was
higher than that in the other groups after 24 hours’s pretreatment
before H/R(t=4.183, P<0.01). B: After H/R, NF- B activity in-
creased significantly in all the groups compared to that before H/R.
However, NF- B activity in E group was much lower than that in
the other groups(t=3.425, P<0.01).
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Some studies have demonstrated that EPO has
cardioprotective effects in vitro. Calvillo et al12found that
rhEPO protected cardiac myocytes isolated from adult
rats and maintained in culture, which decreased the
apoptosis by 50%. The cardioprotection of EPO have
also been proved when Tramontano et al 11 exposed
neonatal rat ventricular myocytes to EPO, which de-
creased apoptosis caused by chronic (72 h) exposure
to hypoxia (25-30 mm Hg).
Someanimal experimentshavealsoshown that EPO
can protect heart in vivo. Tramontano et al 11 ligated the
left anterior descending coronary artery of adult rats
and immediately treated them with intraperitoneal in-
jection of EPO (5 000U/kg body weight).After 60 minutes
of ligation, it was found that terminal deoxynucleotidyl
transferase-mediated dUTP nick end labeling (TUNEL)-
positive cells were significantly decreased in the EPO-
treated hearts. Parsa et al 13 found that EPO improved
left ventricular systolic pressure (LVSP) and diastolic
function of left ventricle in rabbits with ligation of coro-
nary artery. Reduced myocardial infracted volume and
TUNEL-positive cells were also observed.Several other
studies had the similar results.14-17 The discovery of
cardioprotection of EPO has opened up a new field for
cardioprotection research.
EPO-EPOR leads to the homodimerization of
EPOR, with subsequent activation of Janus kinase 2
(JAK2), leading to tyrosine phosphorylation of EPOR,
signal transducers and activators of transcription 5
(STAT5), and a variety of other targets. Subsequently,
Phosphatidyl inositol-3 kinase(PI3K) / protein kinase B
(Akt) , ras/mitogen activated protein kinase (MAPK)
and NF-B are activated. EPO-EPOR interaction also
leads to a rise in intracellular calcium level. Thus, EPO
switches on a complex intracellular network of signal-
ing pathways, and theremay be tissue specific responses
to EPO. Several studies have shown that activation of
PI3K/Akt may be related to EPO’s cardioprotection,11, 13, 18
which inhibits apoptosis of cardiomyocytes. Xu et al19
reported that enhanced expression of heat shock pro-
tein 70 and diminished activity of NF-B were related
to EPO’s cardioprotection in rat heart with ischemia/
reperfusion injury (I-R). Rafiee et al 20 studied the pos-
siblesignal pathwaysrelevant toEPO’s cardioprotection
and they found that EPO protected heart by triggering
multiple intracellular signal pathways, which meant that
the signaling mechanism of EPO’s cardioprotective ef-
fect is very complex. In a word, the signal pathways
associated with EPO’s cardioprotection are still not
identified completely.
Anti-apoptosis and anti-inflammation have been
found to be the two main mechanisms of EPO’s
cardioprotective effect at present. Anti-inflammatory ef-
fect of EPO has been found in the studies on EPO’s
neuroprotection. Brines et al 21 found that EPO treat-
ment reduced inflammation and led to the marked re-
duction in clinical score in the rat model of experimen-
tal autoimmune encephalitis. They also found that in-
flammation was diminished in mice with blunt trauma
caused by closed impact when they were treated with
peritoneal injection of EPO. Villa et al 22 simulated is-
chemia in rats through three-vessel occlusion. In these
rats, EPO treatment signi f icantly decreased
inflammation. EPO’s anti-inflammation in hearts has
also been found. Mitsuma et al 23 investigated the
cardioprotective effects of EPO in rats with experimen-
tal autoimmune myocarditis (EAM). It was found that
EPO suppressed the upregulation of mRNAs of TNF-
and interleukin-6 (IL-6) in the hearts, attenuated the func-
tional and histological severity of EAM, and reduced
apoptosis of cardiomyocytes. Liu et al 24 studied the
mechanism of suppressing the inflammatory responses
after EPO pretreatment in ischemia-reperfusion through
myocardial I-Rrat model. They found that injectionof 5000
units/kg of EPO 24 hours before insult remarkably re-
duced infarct size and neutrophil infiltration. It greatly
attenuated I-R induced NF-B and activator protein-1
(AP-1) activation with decreased TNF-, IL-6 and in-
tracellular adhesion molecule-1 (ICAM-1) production.
They made the conclusion that the cardioprotection of
EPO may be due in part to the suppression of the inflam-
mation via downregulation of NF-B and AP-1 induced
by I-R.
Anti-inflammatory effect has been proved to be one
of the main mechanisms of EPO’s cardioprotection,
but the pathways in which EPO produces anti-inflam-
matory effect are still unclear. In the present study, it
was found that EPO treatment 24 hours prior to insult
significantly reduced the expression of TNF- in
cardiomyocytes after H/R injury, which was in accor-
dance with the previous reports, proving that EPO pre-
t reatment could inhibi t the inf lammat ion in
cardiomyocytes exposed to H/R. Then we found that
NF-B was significantly activated in cardiomyocytes
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during EPO pretreatment and I-Bprotein was mark-
edly reduced at thesametime.The intervention of PDTC
duringpretreatment abolished thesechanges. However,
NF-B activation, upregulation of TNF- gene and
downregulation of I-Bprotein were inhibited in
cardiomyocytes pretreated with EPO after H/R com-
pared to the other groups of cells, which was also abol-
ished by the intervention of PDTC during pretreatment.
It was a very interesting result, demonstrating the acti-
vation of NF-B during EPO pretreatment might be
associated with inhibition of NF-B activation and
upregulation of TNF- gene after H/R. This might be
explained by the self-regulation of NF-B pathway.
NF-B has both positive and negative feedback
pathways. The positive feedback pathway of NF-B is
induced by the upregulation of some pro-inflammatory
factors, such as TNF- and IL-1, whose genes have
the binding site for NF-B. The upregulation of these
pro-inflammatory factors induced by NF-B activation
can induce the aggravating activation of NF-B.
However, NF-B also has the negative feed-back regu-
lating pathway. It is known that promoter of I-B gene
has the binding site for NF-B and activation of NF-B
enhances the transcription of I-B gene. I-B is
a strong inhibitor of NF-B, which binds to NF-B
and forms the inactive heterotrimer, blocking the acti-
vation and translocation into nucleus of NF-B. This
is the very important negative feedback self-regulation
pathway of NF-B, keeping the balance of NF-B
activation and preventing NF-B from over-activation.
In this study, activation of NF-B during EPO pretreat-
ment was found to be related to the decreased activa-
tion of NF-B in cardiomyocytes exposed to H/R,
proved by the intervention of PDTC during EPO
pretreatment, which is an antagonist of NF-B. Inter-
vention of PDTC during EPO pretreatment inhibited the
activation of NF-B during the pretreatment and aboli-
shed the anti-inflammatory effect of EPO pretreatment
in cardiomyocytes exposed to H/R. This could be ex-
plained by the negative feedback pathway of NF-B.
The transcription of I-Bgene was enhanced by NF-
B activation during EPO pretreatment, which then
enhanced the expression of I-Bprotein in
cardiomyocytes exposed to H/R, inhibiting the activa-
tion of NF-B and upregulation of TNF- gene and
producing the anti-inflammatory effect.
Therefore, the negative feedback pathway of NF-B
might be one of the important mechanisms of the anti-
inflammatory effect of EPO in cardiomyocytes exposed
todifferent insults. However, more investigations should
be made to completely clarify the mechanism of EPO’s
anti-inflammatory effect in cardiomyocytes.
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